Copyright Reports & Markets. All rights reserved.

Global Bevacizumab Injection Market Research Report 2021

Request for Sample of this report
Buy now

1 Bevacizumab Injection Market Overview

  • 1.1 Product Overview and Scope of Bevacizumab Injection
  • 1.2 Bevacizumab Injection Segment by Type
    • 1.2.1 Global Bevacizumab Injection Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 100mg
    • 1.2.3 400mg
  • 1.3 Bevacizumab Injection Segment by Application
    • 1.3.1 Global Bevacizumab Injection Sales Comparison by Application: (2021-2027)
    • 1.3.2 Age-related macular degeneration (AMD)
    • 1.3.3 Ovarian Cancer
    • 1.3.4 Others
  • 1.4 Global Bevacizumab Injection Market Size Estimates and Forecasts
    • 1.4.1 Global Bevacizumab Injection Revenue 2016-2027
    • 1.4.2 Global Bevacizumab Injection Sales 2016-2027
    • 1.4.3 Bevacizumab Injection Market Size by Region: 2016 Versus 2021 Versus 2027

2 Bevacizumab Injection Market Competition by Manufacturers

  • 2.1 Global Bevacizumab Injection Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Bevacizumab Injection Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Bevacizumab Injection Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Bevacizumab Injection Manufacturing Sites, Area Served, Product Type
  • 2.5 Bevacizumab Injection Market Competitive Situation and Trends
    • 2.5.1 Bevacizumab Injection Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Bevacizumab Injection Players Market Share by Revenue
    • 2.5.3 Global Bevacizumab Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Bevacizumab Injection Retrospective Market Scenario by Region

  • 3.1 Global Bevacizumab Injection Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global Bevacizumab Injection Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America Bevacizumab Injection Market Facts & Figures by Country
    • 3.3.1 North America Bevacizumab Injection Sales by Country
    • 3.3.2 North America Bevacizumab Injection Revenue by Country
    • 3.3.3 United States
    • 3.3.4 Canada
  • 3.4 Europe Bevacizumab Injection Market Facts & Figures by Country
    • 3.4.1 Europe Bevacizumab Injection Sales by Country
    • 3.4.2 Europe Bevacizumab Injection Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Bevacizumab Injection Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Bevacizumab Injection Sales by Region
    • 3.5.2 Asia Pacific Bevacizumab Injection Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
  • 3.6 Latin America Bevacizumab Injection Market Facts & Figures by Country
    • 3.6.1 Latin America Bevacizumab Injection Sales by Country
    • 3.6.2 Latin America Bevacizumab Injection Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Bevacizumab Injection Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Bevacizumab Injection Sales by Country
    • 3.7.2 Middle East and Africa Bevacizumab Injection Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Bevacizumab Injection Historic Market Analysis by Type

  • 4.1 Global Bevacizumab Injection Sales Market Share by Type (2016-2021)
  • 4.2 Global Bevacizumab Injection Revenue Market Share by Type (2016-2021)
  • 4.3 Global Bevacizumab Injection Price by Type (2016-2021)

5 Global Bevacizumab Injection Historic Market Analysis by Application

  • 5.1 Global Bevacizumab Injection Sales Market Share by Application (2016-2021)
  • 5.2 Global Bevacizumab Injection Revenue Market Share by Application (2016-2021)
  • 5.3 Global Bevacizumab Injection Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Pfizer
    • 6.1.1 Pfizer Corporation Information
    • 6.1.2 Pfizer Description and Business Overview
    • 6.1.3 Pfizer Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Pfizer Bevacizumab Injection Product Portfolio
    • 6.1.5 Pfizer Recent Developments/Updates
  • 6.2 Roche
    • 6.2.1 Roche Corporation Information
    • 6.2.2 Roche Description and Business Overview
    • 6.2.3 Roche Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Roche Bevacizumab Injection Product Portfolio
    • 6.2.5 Roche Recent Developments/Updates
  • 6.3 Eli Lilly
    • 6.3.1 Eli Lilly Corporation Information
    • 6.3.2 Eli Lilly Description and Business Overview
    • 6.3.3 Eli Lilly Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Eli Lilly Bevacizumab Injection Product Portfolio
    • 6.3.5 Eli Lilly Recent Developments/Updates
  • 6.4 Genentech
    • 6.4.1 Genentech Corporation Information
    • 6.4.2 Genentech Description and Business Overview
    • 6.4.3 Genentech Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Genentech Bevacizumab Injection Product Portfolio
    • 6.4.5 Genentech Recent Developments/Updates
  • 6.5 Bayer
    • 6.5.1 Bayer Corporation Information
    • 6.5.2 Bayer Description and Business Overview
    • 6.5.3 Bayer Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Bayer Bevacizumab Injection Product Portfolio
    • 6.5.5 Bayer Recent Developments/Updates
  • 6.6 Amgen
    • 6.6.1 Amgen Corporation Information
    • 6.6.2 Amgen Description and Business Overview
    • 6.6.3 Amgen Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Amgen Bevacizumab Injection Product Portfolio
    • 6.6.5 Amgen Recent Developments/Updates
  • 6.7 Samsung Bioepis
    • 6.6.1 Samsung Bioepis Corporation Information
    • 6.6.2 Samsung Bioepis Description and Business Overview
    • 6.6.3 Samsung Bioepis Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
    • 6.7.5 Samsung Bioepis Recent Developments/Updates
  • 6.8 Centus
    • 6.8.1 Centus Corporation Information
    • 6.8.2 Centus Description and Business Overview
    • 6.8.3 Centus Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Centus Bevacizumab Injection Product Portfolio
    • 6.8.5 Centus Recent Developments/Updates
  • 6.9 Cadila Pharmaceuticals
    • 6.9.1 Cadila Pharmaceuticals Corporation Information
    • 6.9.2 Cadila Pharmaceuticals Description and Business Overview
    • 6.9.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
    • 6.9.5 Cadila Pharmaceuticals Recent Developments/Updates
  • 6.10 Dr Reddy's
    • 6.10.1 Dr Reddy's Corporation Information
    • 6.10.2 Dr Reddy's Description and Business Overview
    • 6.10.3 Dr Reddy's Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Dr Reddy's Bevacizumab Injection Product Portfolio
    • 6.10.5 Dr Reddy's Recent Developments/Updates
  • 6.11 Mylan
    • 6.11.1 Mylan Corporation Information
    • 6.11.2 Mylan Bevacizumab Injection Description and Business Overview
    • 6.11.3 Mylan Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Mylan Bevacizumab Injection Product Portfolio
    • 6.11.5 Mylan Recent Developments/Updates
  • 6.12 Hetero Group
    • 6.12.1 Hetero Group Corporation Information
    • 6.12.2 Hetero Group Bevacizumab Injection Description and Business Overview
    • 6.12.3 Hetero Group Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Hetero Group Bevacizumab Injection Product Portfolio
    • 6.12.5 Hetero Group Recent Developments/Updates
  • 6.13 Biocon
    • 6.13.1 Biocon Corporation Information
    • 6.13.2 Biocon Bevacizumab Injection Description and Business Overview
    • 6.13.3 Biocon Bevacizumab Injection Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Biocon Bevacizumab Injection Product Portfolio
    • 6.13.5 Biocon Recent Developments/Updates

7 Bevacizumab Injection Manufacturing Cost Analysis

  • 7.1 Bevacizumab Injection Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Bevacizumab Injection
  • 7.4 Bevacizumab Injection Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Bevacizumab Injection Distributors List
  • 8.3 Bevacizumab Injection Customers

9 Bevacizumab Injection Market Dynamics

  • 9.1 Bevacizumab Injection Industry Trends
  • 9.2 Bevacizumab Injection Growth Drivers
  • 9.3 Bevacizumab Injection Market Challenges
  • 9.4 Bevacizumab Injection Market Restraints

10 Global Market Forecast

  • 10.1 Bevacizumab Injection Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Bevacizumab Injection by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Bevacizumab Injection by Type (2022-2027)
  • 10.2 Bevacizumab Injection Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Bevacizumab Injection by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Bevacizumab Injection by Application (2022-2027)
  • 10.3 Bevacizumab Injection Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Bevacizumab Injection by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Bevacizumab Injection by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    100mg
    400mg

    Segment by Application
    Age-related macular degeneration (AMD)
    Ovarian Cancer
    Others

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Pfizer
    Roche
    Eli Lilly
    Genentech
    Bayer
    Amgen
    Samsung Bioepis
    Centus
    Cadila Pharmaceuticals
    Dr Reddy's
    Mylan
    Hetero Group
    Biocon

    Buy now